GlassScriptPhysician profile
Trudy S Egan
NPI 1285114405
$4,353.17
in general payments reported to CMS, 2019-2025
22 companies · $954 in 2025
The $954 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $640 · 2022: $887 · 2023: $733 · 2024: $1,139 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,824 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,824.39 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $839.57 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Edwards Lifesciences Corporation | $495.04 | 2021-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $379.89 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Alinity, Infinity |
| Regeneron Healthcare Solutions, INC. | $324.87 | 2022-2024 | Dupixent |
| Abbvie INC. | $247.39 | 2021-2025 | |
| Novo Nordisk INC | $223.21 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $173.88 | 2022 | |
| Madrigal Pharmaceuticals | $145.18 | 2025 | Rezdiffra |
| Alnylam Pharmaceuticals INC. | $143.72 | 2025 | Onpattro |
| Silk Road Medical, INC. | $133.34 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Janssen Scientific Affairs, LLC | $125.00 | 2023 | |
| Boston Scientific Corporation | $125.00 | 2021 | |
| Aimmune Therapeutics, INC. | $124.98 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.82 | 2022 | |
| Myovant Sciences INC. | $121.32 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $110.97 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $109.93 | 2022 | |
| Medtronic, INC. | $97.46 | 2024 | Intellis Adaptivestim |
| Biogen, INC. | $95.19 | 2023 | |
| Scynexis, INC. | $83.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $81.98 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $50.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trudy Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.